Vedolizumab for the Treatment of Ulcerative Colitis and Crohn's Disease

Overview

Journal Immunotherapy

Specialties Allergy & Immunology
Pharmacology

Date 2012 Oct 11

PMID 23046232

Citations 45

Authors

Leon P McLean

Terez Shea-Donohue

Raymond K Cross

Affiliations

Soon will be listed here.

Abstract

Crohn's disease and ulcerative colitis are chronic, relapsing inflammatory disorders of the GI tract. In both Crohn's disease and ulcerative colitis, leukocytic infiltration of the mucosa is associated with epithelial damage. Recently, monoclonal antibodies directed against cell adhesion molecules (CAMs) involved in leukocyte extravasation have been developed. Natalizumab, the first drug brought to market targeting CAMs, is clinically effective but is associated with serious adverse effects including the uncommon, but often fatal, neurological disease progressive multifocal leukoencephalopathy. Vedolizumab targets a subset of the CAMs blocked by natalizumab and is currently in Phase III trials to study its efficacy and safety in patients with inflammatory bowel disease. Here, we discuss the current treatment options available for patients with Crohn's disease or ulcerative colitis, the history of CAM inhibitors, the current state of development of vedolizumab and its future role in inflammatory bowel disease, if approved by regulatory agencies.

Citing Articles

Effectiveness and safety outcomes after long-term (54 weeks) vedolizumab therapy for Crohn's disease: a prospective, real-world observational study including patient-reported outcomes (POLONEZ II).

Liebert A, Klopocka M, Michalak A, Cichoz-Lach H, Talar-Wojnarowska R, Domz Al-Magrowska D Therap Adv Gastroenterol. 2024; 17:17562848241293938.

PMID: 39575158 PMC: 11580093. DOI: 10.1177/17562848241293938.

Corticosteroid-dependent immune checkpoint inhibitor-induced enterocolitis treated with vedolizumab: a case report.

Wan D, Hu C, Ke Q, Zhou T, Ruan L, Tang H J Gastrointest Oncol. 2024; 15(4):1948-1956.

PMID: 39279935 PMC: 11399875. DOI: 10.21037/jgo-24-222.

Effectiveness and safety of vedolizumab and infliximab in biologic-naive patients with Crohn's disease: results from the EVOLVE study.

Mantzaris G, Bressler B, Adsul S, Luo M, Colby C, Brett N Eur J Gastroenterol Hepatol. 2024; 36(3):281-291.

PMID: 38179874 PMC: 10833200. DOI: 10.1097/MEG.0000000000002690.

A Narrative Review of Cytokine Networks: Pathophysiological and Therapeutic Implications for Inflammatory Bowel Disease Pathogenesis.

Vebr M, Pomahacova R, Sykora J, Schwarz J Biomedicines. 2023; 11(12).

PMID: 38137450 PMC: 10740682. DOI: 10.3390/biomedicines11123229.

Pharmacological Therapy in Inflammatory Bowel Diseases: A Narrative Review of the Past 90 Years.

Imbrizi M, Magro F, Coy C Pharmaceuticals (Basel). 2023; 16(9).

PMID: 37765080 PMC: 10537095. DOI: 10.3390/ph16091272.

References

Colombel J, Sandborn W, Reinisch W, Mantzaris G, Kornbluth A, Rachmilewitz D . Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010; 362(15):1383-95. DOI: 10.1056/NEJMoa0904492. View

Hesterberg P, Briskin M, Merrill C, Mackay C, Newman W, Ringler D . Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. Gastroenterology. 1996; 111(5):1373-80. DOI: 10.1053/gast.1996.v111.pm8898653. View

Satsangi J, Jewell D, Rosenberg W, Bell J . Genetics of inflammatory bowel disease. Gut. 1994; 35(5):696-700. PMC: 1374760. DOI: 10.1136/gut.35.5.696. View

Feagan B, Greenberg G, Wild G, Fedorak R, Pare P, McDonald J . Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol. 2008; 6(12):1370-7. DOI: 10.1016/j.cgh.2008.06.007. View

Kandiel A, Fraser A, Korelitz B, Brensinger C, Lewis J . Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005; 54(8):1121-5. PMC: 1774897. DOI: 10.1136/gut.2004.049460. View

Matsuzaki K, Tsuzuki Y, Matsunaga H, Inoue T, Miyazaki J, Hokari R . In vivo demonstration of T lymphocyte migration and amelioration of ileitis in intestinal mucosa of SAMP1/Yit mice by the inhibition of MAdCAM-1. Clin Exp Immunol. 2005; 140(1):22-31. PMC: 1809333. DOI: 10.1111/j.1365-2249.2005.02742.x. View

Feagan B, Sandborn W, Wolf D, Coteur G, Purcaru O, Brabant Y . Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab. Aliment Pharmacol Ther. 2011; 33(5):541-50. DOI: 10.1111/j.1365-2036.2010.04568.x. View

Jess T, Riis L, Vind I, Winther K, Borg S, Binder V . Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis. 2007; 13(4):481-9. DOI: 10.1002/ibd.20036. View

Monteleone G, Pallone F, Macdonald T . Emerging immunological targets in inflammatory bowel disease. Curr Opin Pharmacol. 2011; 11(6):640-5. DOI: 10.1016/j.coph.2011.09.013. View

10.

van der Heijde D, Kivitz A, Schiff M, Sieper J, Dijkmans B, Braun J . Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006; 54(7):2136-46. DOI: 10.1002/art.21913. View

11.

Lim W, Hanauer S . Aminosalicylates for induction of remission or response in Crohn's disease. Cochrane Database Syst Rev. 2010; (12):CD008870. DOI: 10.1002/14651858.CD008870. View

12.

Yu Y, Zhu J, Mi L, Walz T, Sun H, Chen J . Structural specializations of α(4)β(7), an integrin that mediates rolling adhesion. J Cell Biol. 2012; 196(1):131-46. PMC: 3255974. DOI: 10.1083/jcb.201110023. View

13.

Sternthal M, Murphy S, George J, Kornbluth A, Lichtiger S, Present D . Adverse events associated with the use of cyclosporine in patients with inflammatory bowel disease. Am J Gastroenterol. 2008; 103(4):937-43. DOI: 10.1111/j.1572-0241.2007.01718.x. View

14.

Loftus Jr E . Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology. 2004; 126(6):1504-17. DOI: 10.1053/j.gastro.2004.01.063. View

15.

Parikh A, Leach T, Wyant T, Scholz C, Sankoh S, Mould D . Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis. 2011; 18(8):1470-9. DOI: 10.1002/ibd.21896. View

16.

Summers R, SWITZ D, SESSIONS Jr J, Becktel J, Best W, KERN Jr F . National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology. 1979; 77(4 Pt 2):847-69. View

17.

Alfadhli A, McDonald J, Feagan B . Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst Rev. 2005; (1):CD003459. DOI: 10.1002/14651858.CD003459.pub2. View

18.

Sandborn W, Feagan B, Stoinov S, Honiball P, Rutgeerts P, Mason D . Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007; 357(3):228-38. DOI: 10.1056/NEJMoa067594. View

19.

Ardizzone S, Sarzi Puttini P, Cassinotti A, Bianchi Porro G . Extraintestinal manifestations of inflammatory bowel disease. Dig Liver Dis. 2008; 40 Suppl 2:S253-9. DOI: 10.1016/S1590-8658(08)60534-4. View

20.

Agace W . Tissue-tropic effector T cells: generation and targeting opportunities. Nat Rev Immunol. 2006; 6(9):682-92. DOI: 10.1038/nri1869. View